Status:
RECRUITING
COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life
Lead Sponsor:
University Hospital Schleswig-Holstein
Collaborating Sponsors:
Charite University, Berlin, Germany
Wuerzburg University Hospital
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
COVID-19 is a novel disease caused by SARS-CoV-2 that primarily affects the lungs but also various other organs of the body already in early stages of the disease. Due to the multiple organ involvemen...
Detailed Description
Background: COVID-19 is a novel disease caused by SARS-CoV-2. Severity of infection in the acute phase ranges from asymptomatic to critically ill and fatal courses of the disease. Besides the acute r...
Eligibility Criteria
Inclusion
- PCR-confirmed SARS-CoV-2 infection
- living in one of the target areas
- age at least 18 years
- written informed consent
Exclusion
- Acute SARS-CoV-2 infection or reinfection
Key Trial Info
Start Date :
November 16 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04679584
Start Date
November 16 2020
End Date
December 31 2030
Last Update
December 22 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Wuerzburg
Würzburg, Bavaria, Germany, 97080
2
University Hospital Schleswig-Holstein, Campus Kiel
Kiel, Schleswig-Holstein, Germany, 24105
3
University Hospital Charité Berlin
Berlin, Germany, 10117